SGK1 and colorectal carcinoma: Down-regulation of miR-124 expression or silencing of XIST can inhibit the negative regulation of SGK1 by miR-124, thereby reducing the IC50 value of doxorubicin, reducing P-gp and GST-π levels, enhancing cell apoptosis, and enhancing the drug sensitivity of doxorubicin, which provides new ideas for the study of drug resistance treatment strategies for CRC patients [24].